A Study to Evaluate the Benefit of Venetoclax Plus Rituximab Compared With Bendamustine Plus Rituximab in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

NCT02005471 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

389

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Lymphocytic Leukemia

Interventions

DRUG: Bendamustine
DRUG: Venetoclax
DRUG: Rituximab

Sponsor

Hoffmann-La Roche

Collaborators

[object Object]